CELLDEX THERAPEUTICS, Inc. (NASDAQ: CLDX) announced today that data from preclinical studies evaluating the anti-tumor activity of the antibody-drug conjugate ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE